Toralgen is developing a proprietary polybile nanopill delivery technology that has many unique properties. Like other nanoparticles, it can be modified to deliver active drug compounds to targeted sites in the body. In addition, it’s base form offers potential synergistic benefits when delivering therapeutics or diagnostics for diabetes, autoimmune diseases, and cancer.
Our lead program is a based on a
formulation of polymerized ursodeoxycholic acid,
pUDCA, for use in diabetes. Testing to date suggests
the possibility of oral delivery with good biopotency
of diabetic molecules such as insulin and GLP-1. Our goal is to improve diabetes treatment
with a solution that is both cost effective and more
closely mimics the natural metabolic process in the
body than existing delivery methods.